Key statistics
As of last trade BIOAGE Labs Inc (Y7G:MUN) traded at 18.00, 7.78% above its 52-week low of 16.70, set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.30 |
---|---|
High | 18.00 |
Low | 17.30 |
Bid | 18.10 |
Offer | 18.70 |
Previous close | 17.20 |
Average volume | 17.89 |
---|---|
Shares outstanding | 35.85m |
Free float | 34.55m |
P/E (TTM) | -- |
Market cap | 661.05m USD |
EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 16:25 GMT.
More ▼
Press releases
- CHMP issues positive recommendation for approval of lecanemab in the EU
- Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
- BrainTransporter™ dramatically improves antibody delivery to the brain
- Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
- Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
- Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
- Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
- Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
- Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
- Eisai will request reconsideration of initial decision for lecanemab in Australia
More ▼